Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OsteoBiologics (OBI) was a medical technology company specializing in the development of bioabsorbable tissue engineering scaffolds for the repair of musculoskeletal tissues. Founded in 1993 and based in San Antonio, Texas, the company developed a proprietary platform of poly(lactide-co-glycolide) (PLG) polymers to create three-dimensional structures that support the body's natural healing processes. Its lead products, including the TruFit and TruGraft lines, were designed to treat cartilage and bone defects in joints, particularly in sports medicine applications. The TruFit CB product offered a one-step arthroscopic procedure for repairing bone and articular cartilage defects, addressing a significant unmet need in orthopedic surgery. OBI was acquired by Smith & Nephew in 2006 for approximately $72.3 million to bolster their orthopedic and endoscopy portfolios. The acquisition allowed Smith & Nephew to integrate OBI's innovative scaffold technology into its global sports medicine business.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on OsteoBiologics.